vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
High Point
North Carolina
27265
United States
Tel: 336-841-0300 ext 100
Fax: 336-841-0310
Website: http://vtvtherapeutics.com/
75 articles with vTv Therapeutics Inc.
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
7/15/2019
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral presentation at the 2019 Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, July 14 – 18, 2019.
-
vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
6/27/2019
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes.
-
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
6/6/2019
TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia
-
vTv Therapeutics Announces 2019 First Quarter Financial Results and Update
5/1/2019
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events.
-
vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
3/28/2019
Presentation of Results for Subgroup of Patients with Mild Alzheimer’s Disease and Type 2 Diabetes in the STEADFAST Study
-
vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
3/18/2019
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials
-
vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
2/27/2019
Licensing partners also continue to advance GLP-1R agonist, PPAR-delta, and PDE4 programs
-
vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
1/16/2019
Results Found TTP399 Demonstrated a Statistically Significant Improvement in HbA1c Compared to Placebo without Hypoglycemia or Hyperlipidemia
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
11/19/2018
vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City.
-
vTv Therapeutics Announces Third Quarter 2018 Results and Update
11/8/2018
vTv Therapeutics Inc. today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events.
-
vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
10/29/2018
vTv Therapeutics Inc. today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Common Stock on The Nasdaq Capital Market.
-
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
10/24/2018
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease
-
vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
10/16/2018
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session
-
vTv Therapeutics Announces Second Quarter 2018 Results and Update
8/3/2018
vTv Therapeutics Inc. reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.
-
vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
6/22/2018
American Diabetes Association’s 78th Scientific Sessions is held in Orlando, Fla., June 22–26, 2018.
-
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
-
vTv Therapeutics reported the second part of its Phase III Alzheimer’s disease study failed to meet co-primary efficacy endpoints.